A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.

@article{Desai2005API,
  title={A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.},
  author={A. Desai and R. Schilsky and A. Young and L. Janisch and W. Stadler and N. Vogelzang and S. Cadden and J. Wright and M. Ratain},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2005},
  volume={16 6},
  pages={
          958-65
        }
}
  • A. Desai, R. Schilsky, +6 authors M. Ratain
  • Published 2005
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
BACKGROUND This study of GTI-2040, a 20-mer phosphorothioate oligonucleotide complementary to the messenger ribonucleic acid (mRNA) of the R2 subunit of ribonucleotide reductase (RNR), was conducted to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of the agent in patients with advanced solid tumors or lymphoma. Plasma pharmacokinetics of GTI-2040 and suppression of RNR expression in peripheral blood mononuclear cells were also studied. PATIENTS AND METHODS GTI… Expand
Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia
TLDR
GTI-2040 and high-dose AraC were coadministered safely with successful reduction of the intended R2 target and encouraging clinical results, suggesting intracellular drug accumulation over time. Expand
A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors
TLDR
The combination of GTI-2040 and gemcitabine has an acceptable safety profile in a heavily pre-treated patient population with advanced solid tumors and several patients had prolonged stable disease. Expand
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study
TLDR
There were no objective responses to GTI-2040 in this study; 7/24 patients were able to complete the predetermined three infusion cycles and pharmacokinetic and pharmacodynamic studies were performed, indicating a trend towards increasing intracellular drug levels and decreasing RRM2 gene expression with increasing doses. Expand
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
TLDR
The PSA response rate of GTI-2040 in combination with docetaxel and prednisone just met the minimum phase II criteria for further enrollment, however, after evaluation of all the clinical data, further study of this dose and schedule in CRPC was not recommended. Expand
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma
TLDR
Only one patient, treated at a GTI 2040 dose of 185 mg/m2/day in the phase I portion of the protocol, responded, and Toxicities and GTI-2040 pharmacokinetics were consistent with previously reported results. Expand
Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2
TLDR
In rats and monkeys, GTI-2040 was reasonably well tolerated and showed reversible toxicities when administered at doses up to 50 mg/kg/day for 21 days, which were typical for the phosphorothioate oligonucleotide class of compounds. Expand
A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium
  • N. Leighl, S. Laurie, +10 authors M. Moore
  • Medicine
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2009
TLDR
Activity of the combination at RP2D, GTI-2040 5 mg/kg/d × 14 days by CVI plus docetaxel 75 mg/m2 does not seem superior to docetAXel alone in previously treated NSCLC. Expand
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study
TLDR
A combination of GTI-2040, capecitabine and oxaliplatin is feasible in patients with advanced solid tumors and two of six patients had stable disease at the maximum tolerated dose and one patient had a partial response at a higher dose level. Expand
GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.
TLDR
Results expand the potential clinical applications of GTI-2040 to include combination therapy with IFNalpha, which resulted in increased apoptosis and decreased proliferation when investigated against human renal cell carcinoma tumors xenografted into mice. Expand
Pharmacokinetic-Pharmacodynamic Studies Of 5-Azacytidine In Combination With Gti-2040
TLDR
A sensitive HPLC method has been developed to determine the intracellular aracytidine triphosphate (Ara-CTP) level, and GTI-2040 was found to down-regulate R2 mRNA and protein levels in a dose dependent manner. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
  • M. Morris, W. Tong, +10 authors H. Scher
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002
TLDR
Fatigue and transient reversible elevations of serum transaminases (grades 2-3) became apparent after >or=7 days of treatment, and both reactions were believed to be drug related. Expand
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.
  • J. Waters, A. Webb, +4 authors F. Cotter
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
TLDR
B cl-2 antisense therapy is feasible and shows potential for antitumor activity in NHL and downregulation of Bcl-2 protein suggests a specific antisense mechanism. Expand
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
TLDR
This study demonstrates that G3139 can be administered safely with FLAG chemotherapy and down-regulate its target, Bcl-2, and justifies the current plans for a phase 3 study in previously untreated high-risk AML. Expand
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
  • C. Rudin, J. Holmlund, +10 authors M. Ratain
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2001
TLDR
The data suggest that the efficacy and toxicity profiles of antisense oligonucleotides may be highly dependent on the schedule of administration and support the analysis of the putative molecular target in the evaluation of novel therapeutics. Expand
GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
TLDR
The results of these studies indicate that GTI-2040 can act as a selective and specific anticancer agent against a broad range of human tumors. Expand
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
PURPOSE To determine the clinical response rate of the combination of weekly intravenous (IV) gemcitabine with continuous infusion fluorouracil (5-FU) in patients with metastatic renal cell carcinomaExpand
A Phase I trial of h‐ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma
TLDR
An initial clinical study of the safety and tolerability of an intravenous infusion of ISIS 2503 in patients with advanced cancer is reported. Expand
Antisense--time to shoot the messenger.
  • B. Kuss, F. Cotter
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 1999
TLDR
A large base of knowledge of pharmacodynamics and toxicology profiles, has been built from extensive in vivo testing and phase I and II human clinical trials, and antisense therapy has been gaining ground. Expand
Inhibition of coagulation by a phosphorothioate oligonucleotide.
TLDR
In this study, inhibition of clotting times was characterized by determining the time course of both APTT and plasma oligonucleotide following intravenous infusion of ISIS 2302 in cynomolgus monkeys, indicating that the intrinsic pathway (APTT) was more sensitive to inhibition than the extrinsic pathway (PT). Expand
Chemotherapy of advanced colorectal carcinoma: Fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin A phase III trial by the Eastern Cooperative Oncology Group (EST 1278)
TLDR
Patients treated with FU or FU + HU experienced substantially less toxicity than those on the other treatment arms and no significant treatment differences with respect to response, response, or median survival duration. Expand
...
1
2
3
...